Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

Leukemia. 2014 Nov;28(11):2251-4. doi: 10.1038/leu.2014.206. Epub 2014 Jul 3.

Authors

W E Pierceall¹, S L Warner², R J Lena¹, C Doykan¹, N Blake¹, M Elashoff¹, D V Hoff³, D J Bearss², M H Cardone¹, L Andritsos⁴, J C Byrd⁴, M C Lanasa⁵, M R Grever⁴, A J Johnson⁴

Affiliations

¹ Eutropics Inc., Cambridge, MA, USA.
² Tolero Pharmaceuticals, Inc., Lehi, UT, USA.
³ 1] Tolero Pharmaceuticals, Inc., Lehi, UT, USA [2] Translational Genomics Research Institute, Scottsdale, AZ, USA.
⁴ Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
⁵ Department of Medicine, Duke Cancer Institute, Durham, NC, USA.

No abstract available

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use
Drug Resistance, Neoplasm / genetics
Female
Flavonoids / therapeutic use*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
Male
Middle Aged
Mitochondria / physiology*
Piperidines / therapeutic use*
bcl-X Protein / genetics*

Substances

Antineoplastic Agents
BCL2L1 protein, human
Flavonoids
Piperidines
bcl-X Protein
alvocidib

Grants and funding